Meridian Bioscience Cash on Hand 2006-2019 | VIVO

Meridian Bioscience cash on hand from 2006 to 2019. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Meridian Bioscience Annual Cash on Hand
(Millions of US $)
2018 $60
2017 $57
2016 $47
2015 $50
2014 $43
2013 $44
2012 $32
2011 $24
2010 $38
2009 $61
2008 $49
2007 $49
2006 $40
2005 $33
Meridian Bioscience Quarterly Cash on Hand
(Millions of US $)
Q2 2019 $66
Q1 2018 $62
Q4 2018 $60
Q3 2018 $58
Q2 2018 $56
Q1 2017 $55
Q4 2017 $57
Q3 2017 $55
Q2 2017 $55
Q1 2016 $49
Q4 2016 $47
Q3 2016 $46
Q2 2016 $49
Q1 2015 $53
Q4 2015 $50
Q3 2015 $46
Q2 2015 $43
Q1 2014 $50
Q4 2014 $43
Q3 2014 $39
Q2 2014 $38
Q1 2013 $44
Q4 2013 $44
Q3 2013 $40
Q2 2013 $39
Q1 2012 $33
Q4 2012 $32
Q3 2012 $28
Q2 2012 $24
Q1 2011 $26
Q4 2011 $24
Q3 2011 $26
Q2 2011 $28
Q1 2010 $41
Q4 2010 $38
Q3 2010 $58
Q2 2010 $61
Q1 2009 $67
Q4 2009 $61
Q3 2009 $53
Q2 2009 $48
Q1 2008 $50
Q4 2008 $49
Q3 2008 $47
Q2 2008 $45
Q1 2007 $54
Q4 2007 $49
Q3 2007 $46
Q2 2007 $40
Q1 2006 $42
Q4 2006 $40
Q3 2006 $36
Q2 2006 $31
Q1 2005 $33
Q4 2005 $33
Q3 2005 $4
Q2 2005 $4
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.462B $0.214B
Meridian Bioscience, Inc. is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and biopharmaceutical enabling technologies that help deliver answers. Its products provide accuracy, simplicity and speed for the early diagnosis and treatment of common medical conditions, such as C. difficile, H. pylori, foodborne diseases and respiratory infections. In addition, the company develops and manufactures a variety of biological and non-biological materials used in proficiency testing programs. Meridian diagnostic products are used outside of the human body and require little or no special equipment. Meridian Bioscience designs their products to enhance the well-being of the patient-while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal infections, serology, parasitology and fungal disease diagnosis.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $134.025B 26.02
Medtronic (MDT) Ireland $117.659B 17.20
Stryker (SYK) United States $68.704B 24.52
Boston Scientific (BSX) United States $51.899B 24.88
Baxter (BAX) United States $38.763B 24.43
Zimmer Biomet Holdings (ZBH) United States $23.843B 15.32
Smith & Nephew SNATS (SNN) United Kingdom $18.247B 0.00
ResMed (RMD) United States $16.172B 30.90
Canopy Growth (CGC) Canada $15.352B 0.00
Bio-Rad Laboratories (BIO) United States $8.842B 46.88
Aurora Cannabis (ACB) Canada $8.802B 86.80
Perrigo (PRGO) Ireland $6.755B 11.42
Hill-Rom Holdings (HRC) United States $6.504B 19.72
Insulet (PODD) United States $6.200B 451.74
GW Pharmaceuticals (GWPH) United Kingdom $5.280B 0.00
Haemonetics (HAE) United States $5.104B 41.87
ICU Medical (ICUI) United States $4.630B 27.62
Hutchison China MediTech (HCM) China $3.565B 0.00
NuVasive (NUVA) United States $3.164B 25.84
Neogen (NEOG) United States $3.071B 49.94
Agios Pharmaceuticals (AGIO) United States $2.941B 0.00
Quidel (QDEL) United States $2.233B 23.17
National Vision Holdings (EYE) United States $2.120B 45.18
Aphria (APHA) $1.712B 0.00
Cardiovascular Systems (CSII) United States $1.377B 790.80
Phibro Animal Health (PAHC) United States $1.168B 17.50
AtriCure (ATRC) United States $1.136B 0.00
VAREX IMAGING (VREX) United States $1.083B 22.98
Lantheus Holdings (LNTH) United States $0.941B 25.00
NanoString Technologies (NSTG) United States $0.941B 0.00
Omeros (OMER) United States $0.914B 0.00
MacroGenics (MGNX) United States $0.913B 0.00
PetIQ (PETQ) United States $0.806B 19.58
Cerus (CERS) United States $0.754B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.753B 21.11
TG Therapeutics (TGTX) United States $0.609B 0.00
LeMaitre Vascular (LMAT) United States $0.541B 26.20
OraSure Technologies (OSUR) United States $0.529B 24.37
Surmodics (SRDX) United States $0.527B 76.59
Quanterix (QTRX) United States $0.498B 0.00
Evolus (EOLS) United States $0.440B 0.00
BioLife Solutions (BLFS) United States $0.343B 107.18
Utah Medical Products (UTMD) United States $0.311B 21.52
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.310B 0.00
Vapotherm (VAPO) United States $0.282B 0.00
Rockwell Medical (RMTI) United States $0.267B 0.00
Zynex (ZYXI) United States $0.240B 24.80
Owens & Minor (OMI) United States $0.226B 4.79
Cytosorbents (CTSO) United States $0.223B 0.00
Bovie Medical (APYX) United States $0.204B 0.00
Chimerix (CMRX) United States $0.179B 0.00
Chembio Diagnostics (CEMI) United States $0.134B 0.00
Fonar (FONR) United States $0.134B 7.05
Surface Oncology (SURF) United States $0.111B 0.00
Female Health (VERU) United States $0.103B 0.00
United-Guardian (UG) United States $0.094B 20.70
Neurotrope (NTRP) United States $0.091B 0.00
Insys Therapeutics (INSY) United States $0.079B 0.00
Trinity Biotech (TRIB) Ireland $0.058B 20.00
Oramed Pharmaceuticals (ORMP) United States $0.053B 0.00
ImmuCell (ICCC) United States $0.045B 0.00
Senestech (SNES) United States $0.042B 0.00
GUARDION HEALTH (GHSI) United States $0.032B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.029B 0.00
BRAINSWAY LTD (BWAY) Israel $0.027B 0.00
Valeritas Holdings (VLRX) United States $0.025B 0.00
Capricor Therapeutics (CAPR) United States $0.011B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.011B 0.00
Cellectar Biosciences (CLRB) United States $0.010B 0.00
Akers Biosciences Inc (AKER) United States $0.009B 0.00
NeuroMetrix (NURO) United States $0.006B 4.60